Advertisement

Post-transplant Cardiovascular Disease

  • Phuong-Anh T. Pham
  • Carmen Slavov
  • Phuong-Thu T. Pham
  • Alan H. Wilkinson
Chapter

Abstract

Renal transplantation is the treatment modality of choice for virtually all suitable candidates with end-stage renal disease. Compared to dialysis, kidney transplantation improves both patient survival and quality of life. Studies suggest that the survival advantage of transplantation may be largely attributed to the reduction in cardiovascular disease (CVD) associated with the improvement in renal function following a successful renal transplant. In a retrospective analysis of the United States Renal Data System consisting of more than 60,000 adult primary kidney transplant recipients transplanted between 1995 and 2000 and more than 66,000 adult wait-listed patients over the same time period, Meier-Kriesche et al. demonstrated a progressive decrease in cardiovascular death rates by renal transplant vintage for both diabetic and non-diabetic recipients of both living and deceased donor transplants.

Keywords

Transplant Recipient Coronary Artery Calcification Chronic Kidney Disease Patient Renal Transplant Recipient Coronary Artery Calcification Score 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Meier-Kriesche HU, Schold JD, Kaplan B. Preservation of long-term renal allograft survival: a challenge for the years to come. Am J Transplant 2005;5:632–633.CrossRefGoogle Scholar
  2. 2.
    Pham PT, Pham PC, Danovitch GM. Cardiovascular disease posttransplant. Semin Nephrol 2007;27(4):430–444.CrossRefPubMedGoogle Scholar
  3. 3.
    Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006;82:603–611.CrossRefPubMedGoogle Scholar
  4. 4.
    Opelz G, Wujciak T, Ritz E et al. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998;53:217–222.CrossRefPubMedGoogle Scholar
  5. 5.
    Kasiske BL, Anjum S, Shah R et al. Hypertension after transplantation. Am J Kidney Dis 2004;43:1071–1081.CrossRefPubMedGoogle Scholar
  6. 6.
    Premasathian NC, Muehrer R, Brazy PC et al. Blood pressure control in kidney transplantation. Therapeutic implications. J Hum Hypertens 2004;18:871–877.CrossRefPubMedGoogle Scholar
  7. 7.
    Fricke L, Doehn C, Steinhoff J et al. Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy? Transplantation 1998;65(9):1182–1187.CrossRefPubMedGoogle Scholar
  8. 8.
    Kreis H, Oberbauer R, Camoistol JM. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004;15:809–817.CrossRefPubMedGoogle Scholar
  9. 9.
    Margreiter R, Pohanka E, Sparacio V et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing cyclosporine-related side effects. Transplant Int 2005;18(7):816–823.CrossRefGoogle Scholar
  10. 10.
    Ligtenberg G, Hene RJ, Blankestijn PJ et al. Cardiovascular risk factors in renal transplant patients: cyclosporine A versus tacrolimus. J Am Soc Nephrol 2001;12(2):368–373.PubMedGoogle Scholar
  11. 11.
    Pascual J, Van Hooff JP, Salmela K. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplantation. Transplantation 2006;85:55–61.CrossRefGoogle Scholar
  12. 12.
    EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.2. Cardiovascular risks. Arterial hypertension. Nephrol Dial Transplant 2000;17:25–26, [Abstract].Google Scholar
  13. 13.
    Kasiske BL, Chakkera H, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2001;11:1735–1743.Google Scholar
  14. 14.
    Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.CrossRefPubMedGoogle Scholar
  15. 15.
    Agoda LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomised controlled trial. JAMA 2001;285:2719–2728.CrossRefGoogle Scholar
  16. 16.
    De C, Karas M, Nguyen P et al. Different effects of nifedipine and amlodipine on circulating catecholamines levels in essential hypertensive patients. J Hypertens 1998;16:1357–1369.CrossRefGoogle Scholar
  17. 17.
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blockers vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.CrossRefGoogle Scholar
  18. 18.
    Hiremath S, Fergusson D, Doucette S et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007;7:2350–2360.CrossRefPubMedGoogle Scholar
  19. 19.
    Jennings DL, Taber DJ. Use of rennin-angiotensin-aldosterone inhibitors within the first eight to twelve weeks after renal transplantation. Ann Pharm Ther 2008;42(1):116–120.Google Scholar
  20. 20.
    Tylicki L, Biedunkiewicz B, Chamienia A et al. Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 2007;7:243–248.CrossRefPubMedGoogle Scholar
  21. 21.
    Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807–818.CrossRefPubMedGoogle Scholar
  22. 22.
    Kasiske BL, de Mattos A, Flechner SM et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008;8:1384–1392.CrossRefPubMedGoogle Scholar
  23. 23.
    Hoogeven RC, Ballantyne CM, Pownall HJ et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins. Transplantation 2001;72:1244–1250.CrossRefGoogle Scholar
  24. 24.
    Collins R, Armitage J, Parish J et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363(9411):757–767.CrossRefPubMedGoogle Scholar
  25. 25.
    Messereli AW, Aronow HD, Sprecker DL. The Lescol Intervention Prevention Study (LIPS): start all patients on statin early after PCI. Clev Clin J Med 2003;70:561–566.CrossRefGoogle Scholar
  26. 26.
    Holdaas H, Fellstrom B, Jardin AG et al. Beneficial effects of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 2005;20:974–980.CrossRefPubMedGoogle Scholar
  27. 27.
    Fellstrom B, Holdaas H, Jardine AG et al. Effects of fluvastatin end points in the Assessment of Lescol in renal transplantation (ALERT) trial. Kidney Int 2004;66:1549–1555.CrossRefPubMedGoogle Scholar
  28. 28.
    Masterson R, Hweitson T, Leikis M et al. Impact of statin treatment on 1-year functional and histologic renal allograft outcome. Transplantation 2005;80:332–338.CrossRefPubMedGoogle Scholar
  29. 29.
    Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553–564.CrossRefPubMedGoogle Scholar
  30. 30.
    Chuang P, Langone AJ. Ezetimide reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors. Am J Ther 2007;14(5):438–441.CrossRefPubMedGoogle Scholar
  31. 31.
    Turk TR, Voropaeva E, Kohnle M et al. Ezetimide treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant 2008;23(1):369–373.CrossRefPubMedGoogle Scholar
  32. 32.
    Kasiske BL, Cosio FG, Beto J et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4(Suppl 7):13–53.CrossRefPubMedGoogle Scholar
  33. 33.
    Chuang P, Gibney EM, Chan L et al. Predictors of cardiovascular events and associated mortality within two years of kidney transplantation. Transplant Proc 2004;36(5):1387–1391.CrossRefPubMedGoogle Scholar
  34. 34.
    Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000;11(4):753–759.PubMedGoogle Scholar
  35. 35.
    Lentine KL, Rocca-Rey LA, Bacchi G et al. Obesity and cardiac risk after kidney transplantation: Experience at one center and comprehensive literature review. Transplantation 2008;86(2):303–312.CrossRefPubMedGoogle Scholar
  36. 36.
    Abbott KC, Yuan CM, Taylor AJ et al. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003;14:2358–2365.CrossRefPubMedGoogle Scholar
  37. 37.
    Abbott KC, Reynolds JC, Taylor AJ et al. Hospitalized atrial fibrillation after renal transplantation in the United States. Am J Transplant 2003;3:471–476.CrossRefPubMedGoogle Scholar
  38. 38.
    Canzanello VJ, Schwartz L, Tater SJ et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus FK(506). Liver Transplant Surg 1997;3:1–9.CrossRefGoogle Scholar
  39. 39.
    Newcombe V, Blanch A, Slater GH et al. Laparoscopic adjustable gastric banding prior to renal transplantation. Obes Surg 2005;15:567–570.CrossRefPubMedGoogle Scholar
  40. 40.
    Wikelmayer WC, Kramer R, Curhan GC et al. Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. J Am Soc Nephrol 2005;16:255–260.CrossRefGoogle Scholar
  41. 41.
    Zoungas S, McGrath BP, Branley P et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic acid Supplementation trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol 2006;47:1108–1116.CrossRefPubMedGoogle Scholar
  42. 42.
    Mann JF, Sheridan P, McQueen MJ et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney – results of the renal HOPE-2 study. Nephrol Dial Transplant 2008;23:645–653.CrossRefPubMedGoogle Scholar
  43. 43.
    Bostom AG, Carpenter MA, Hunsicker L et al. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. Am J Kidney Dis 2009;53:121–128.CrossRefPubMedGoogle Scholar
  44. 44.
    Fernando-Fresnedo G, Escallada R, Rodrigo E et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002;73:1345–1348.CrossRefGoogle Scholar
  45. 45.
    Roodnat JJ, Mulder PG, Rischen-Vos J et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001;72:438–444.CrossRefPubMedGoogle Scholar
  46. 46.
    Djamali A, Becker YT, Simmons WD et al. Increasing hematocrit reduces early posttransplant cardiovascular risk in diabetic transplant recipients. Transplantation 2003;76:816–820.CrossRefPubMedGoogle Scholar
  47. 47.
    Imoagene-Oyedeji AE, Rosas SE, Doyle AM et al. Posttransplant anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol 2006;17:3240–3247.CrossRefPubMedGoogle Scholar
  48. 48.
    Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20):2085–2098.CrossRefPubMedGoogle Scholar
  49. 49.
    Szczech L, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791–798.CrossRefPubMedGoogle Scholar
  50. 50.
    Ishitani MB, Milliner DS, Kim DY et al. Early subclinical coronary artery calcification in young adults who were pediatric kidney transplant recipients. Am J Transplant 2005;5:1689–1693.CrossRefPubMedGoogle Scholar
  51. 51.
    Mao SS, Pal RS, McKay CR et al. Comparison of coronary artery calcium scores between electron beam computed tomography and 64-Multidetector Computed Tomographic scanner. J Comput Assist Tomogr 2009;33(2):175–178.CrossRefPubMedGoogle Scholar
  52. 52.
    Budoff MJ, McClelland RI, Chung H et al. Reproducibility of coronary artery calcified plaque with cardiac 64-MDCT: The Multi-Ethnic Study of Atherosclerosis. Am J Roentgenol 2009;192(3):613–617.CrossRefGoogle Scholar
  53. 53.
    Budoff MJ, Achenbach S, Blumenthal RS et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, and Committee on Cardiac Imaging. Council on Clinical Cardiology. Circulation 2006;114:1761–1791.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag US 2010

Authors and Affiliations

  • Phuong-Anh T. Pham
    • 1
  • Carmen Slavov
    • 2
  • Phuong-Thu T. Pham
    • 3
  • Alan H. Wilkinson
    • 3
  1. 1.Mercy General Hospital, Heart and Vascular Institute, Cardiovascular DiseasesSacramentoUSA
  2. 2.Division of Nephrology, Department of Medicine, Kidney and Pancreas Transplant ProgramDavid Geffen School of Medicine at UCLA, Ronald Reagan UCLA Medical CenterLos AngelesUSA
  3. 3.Division of Nephrology, Department of Medicine, Kidney and Pancreas Transplant ProgramDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations